Roche Molecular Systems
Roche Molecular Systems develops PCR-based molecular diagnostic instruments and tests under the cobas and LightCycler brands, serving clinical laboratories, hospitals, blood screening facilities, and point-of-care settings worldwide as a subsidiary of F. Hoffmann-La Roche Ltd.
- Company typePrivate
- Founded1991
- HeadquartersPleasanton, United States
- Headcount5,001–10,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Roche Molecular Systems does
Roche Molecular Systems, Inc. is a wholly-owned subsidiary of F. Hoffmann-La Roche Ltd, incorporated in California and headquartered in Pleasanton. Founded in 1991 as part of Roche Diagnostics, the company develops and commercializes molecular diagnostic instruments, assays, and reagents based primarily on polymerase chain reaction (PCR) and nucleic acid testing (NAT) technologies. Its portfolio is organized around the cobas brand and includes the cobas 5800, 6800/8800, eplex, prime pre-analytical, and Liat systems, complemented by the LightCycler PRO and Digital LightCycler real-time PCR platforms, the MagNA Pure 96 nucleic acid purification instrument, and the navify digital integration suite that connects instruments with LIS, HIS, and EMR systems.
The company serves clinical laboratories, hospitals, blood and plasma screening facilities, point-of-care settings, and research/lab-developed testing sites across infectious disease, cervical health, sexual health, respiratory, transplant, and oncology applications. Its go-to-market is enterprise field sales through the global Roche Diagnostics commercial organization, with ongoing technical, training, and market-access support. Revenue is generated across three streams: capital equipment (instruments), high-margin recurring consumables and assays (test panels, reagents), and service/support contracts.
As an operating subsidiary of a public Swiss parent (SIX: RO), Roche Molecular Systems benefits from the parent's distribution scale, regulatory infrastructure, and R&D depth. Recent strategic emphasis has been on regulatory-led category expansion — notably the July 2024 FDA approval of cobas HPV self-collection in healthcare settings — and on deepening digital integration via navify to lock in installed-base economics across thousands of globally deployed molecular lab systems.
Roche Molecular Systems firmographics
Firmographics- Name
- Roche Molecular Systems
- Legal name
- Roche Molecular Systems, Inc.
- Website
- https://molecular.roche.com
- Company type
- Private
- Founded year
- 1991
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- Roche Molecular Systems develops PCR-based molecular diagnostic instruments and tests under the cobas and LightCycler brands, serving clinical laboratories, hospitals, blood screening facilities, and point-of-care settings worldwide as a subsidiary of F. Hoffmann-La Roche Ltd.
- Ownership category
- akta.pro rank
Roche Molecular Systems industry classification
Industry- Product category
- Molecular Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD)
- akta.pro secondary industry
- Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges) (HLAHAOAI)
Keywords
Where Roche Molecular Systems is headquartered
LocationHeadquarters
- HQ city
- Pleasanton
- HQ country
- United States
- HQ region
- North America
Markets served
Roche Molecular Systems business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Molecular Diagnostic Instruments and Systems: Sale of automated molecular diagnostic systems including cobas 5800, 6800/8800, eplex, LightCycler, and related instruments. These are capital equipment purchases with ongoing consumables revenue.
- Molecular Assays and Reagents: Recurring revenue from molecular test assays, panels (BCID-GN, respiratory pathogen panels, HPV tests), and consumables required to run on Roche molecular platforms.
- Service and Support Contracts: Roche Diagnostics services including consulting, implementation, Medical Affairs, Training, Market Access teams, and ongoing technical support.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels4 records
Roche Molecular Systems product offering
Product offeringCore offering
Roche Molecular Systems develops, manufactures, and commercializes molecular diagnostic instruments, PCR-based assays and reagents, pre-analytical automation, and digital integration software used by clinical laboratories, hospitals, blood screening facilities, and point-of-care settings. The portfolio covers infectious disease screening and diagnosis, cervical cancer screening, sexual health, respiratory pathogen detection, transplant transmitted infection screening, and oncology testing, with thousands of cobas and LightCycler systems installed globally.
Product overview
Roche Molecular Systems offers a comprehensive portfolio of molecular laboratory solutions organized around the cobas brand platform and supporting instruments. The portfolio includes high-throughput automated PCR systems (cobas 5800, cobas 6800/8800), pre-analytical automation (cobas prime), syndromic testing platforms (cobas eplex with various assay panels including BCID-GN and respiratory panels), Point of Care solutions (cobas Liat), real-time PCR systems (LightCycler PRO), nucleic acid purification instruments (MagNA Pure 96), digital PCR platforms (Digital LightCycler), and digital integration software (navify Integrator). The solutions span from centralized laboratory testing to Point of Care settings, covering infectious diseases, cervical health, sexual health, respiratory, transplant, and oncology applications.
Differentiator
Problem solved
Functional benefit
Brands
- cobas: A comprehensive brand for Roche's molecular testing systems including cobas 5800, cobas 6800/8800, cobas eplex, cobas Liat, and associated assays for various diagnostic applications including HPV, respiratory pathogens, and blood culture identification.
- LightCycler
- MagNA Pure
- navify
Products and services
- cobas 5800 system Automated PCR-based nucleic acid testing system designed for trained professionals in laboratory settings with integrated workflow automation for sample-to-result molecular testing.
- cobas 6800/8800 Systems Automated systems combining instrumentation, consumables, reagents, and data management to provide efficient workflow from sample processing to result interpretation for PCR-based nucleic acid testing in clinical laboratories.
- cobas prime pre-analytical system Automated pre-analytical sample preparation system for molecular diagnostic testing that minimizes manual tasks and supports workflow automation in clinical laboratories.
- cobas eplex system Rapid multiplex diagnostics platform with sample-to-answer automation, LIS integration, and scalable design supporting syndromic molecular testing.
- cobas eplex BCID-GN panel Qualitative nucleic acid multiplex in vitro diagnostic test for simultaneous detection and identification of gram-negative bacterial organisms and antimicrobial resistance determinants in positive blood culture, run on the cobas eplex system.
- cobas eplex respiratory pathogen panel 2 Multiplex respiratory pathogen panel for use on the cobas eplex system for molecular detection of respiratory pathogens.
- cobas Liat system Point of Care PCR system providing gold-standard PCR technology for near-patient molecular testing in primary care and hospital settings.
- cobas SARS-CoV-2 & Influenza A/B Multiplex molecular test for simultaneous detection and differentiation of SARS-CoV-2 and Influenza A/B viruses, run on the cobas Liat point-of-care PCR system.
- LightCycler PRO system Real-time PCR system integrating innovative technology and Roche manufacturing to deliver accurate real-time PCR results for clinical and research laboratories.
- MagNA Pure 96 Instrument High-throughput instrument for automated nucleic acid purification designed to increase laboratory productivity in clinical and research settings.
- Digital LightCycler System Semi-automated PCR platform designed for precise detection and absolute quantification of nucleic acid targets using digital PCR technology.
- Lab Module for navify Integrator Software platform providing bi-directional, standardized and secure data integration and communication between laboratory data sources (instruments, LIS, HIS, EMRs) and cloud-based products.
- cobas HPV Test (with self-collection indication) FDA-approved HPV molecular test for cervical cancer screening; with the 2024-07-24 FDA expansion, it can be used with self-collected vaginal samples in healthcare settings.
Companies that use Roche Molecular Systems
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles4 records
Roche Molecular Systems technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration4 records
Feature9 records
Roche Molecular Systems partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Vall d'Hebron Laboratory (Barcelona)coreCase study partnership where Vall d'Hebron laboratory implemented the cobas prime pre-analytical system to transform molecular workflows. Dr. Francisco Rodriguez Frias, Molecular Area Head, and team share their experience with Roche molecular solutions.
- NCI (National Cancer Institute) Last Mile InitiativecoreNCI's Last Mile Initiative supported the research leading to FDA approval of cobas HPV test for self-collection in healthcare settings, with ongoing SHIP Trial testing home-based self-collection.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
Roche Molecular Systems competitors and assessment
Company assessmentEmerging players
- Rheonix: Rheonix develops fully automated molecular testing platforms (e.g., Rheonix COVID-19 MDx) and lab-on-a-chip technologies for high-throughput sample-to-answer PCR. It is an emerging player in molecular diagnostics with a comparable automation and multiplexing thesis to Roche's cobas eplex.
- DiaSorin: DiaSorin (which acquired Luminex) offers molecular diagnostics solutions including the Liaison MDX and legacy Luminex multiplexing platforms. It competes with Roche's molecular menu in select infectious disease and specialty testing segments.
- Seegene: Seegene develops multiplex PCR assays and automated systems (e.g., Allplex) for syndromic and infectious disease testing. It is an emerging player whose menu and automation approach overlap with cobas eplex panels.
Direct peers
- Hologic: Hologic's Panther and Panther Fusion systems provide fully automated molecular testing with a strong franchise in women's health (Aptima HPV, CT/NG, Trichomonas). It directly competes with cobas HPV and the broader Roche molecular menu in hospital and reference labs.
- bioMérieux: bioMérieux's BioFire FilmArray systems lead in syndromic molecular testing (respiratory, bloodstream, GI, meningitis panels). It directly competes with cobas eplex panels and Roche's broader syndromic offering.
- Becton Dickinson (BD): BD's BD MAX system and BD COR MX offer automated PCR-based syndromic and infectious disease testing. It competes with cobas eplex and cobas 6800/8800 in hospital labs and integrated delivery networks.
- QIAGEN: QIAGEN provides sample-prep technologies (QIAamp, QIAsymphony) and the QIAstat-Dx syndromic PCR platform. Its molecular diagnostics portfolio overlaps with Roche's MagNA Pure sample prep and cobas eplex syndromic testing.
- Abbott Molecular: Abbott's m2000 and Alinity m systems offer automated PCR-based molecular testing for infectious disease, viral load, and women's health. Abbott directly competes with Roche's cobas platform in centralized labs and hospital networks globally.
- QuidelOrtho: QuidelOrtho (merger of Quidel and Ortho Clinical Diagnostics) offers the Savanna molecular platform for rapid PCR testing in point-of-care settings. It competes with cobas Liat and other Roche point-of-care molecular solutions.
- Cepheid (Danaher): Cepheid is the leading competitor in PCR-based molecular diagnostics with its GeneXpert system and extensive Xpert test menu (infectious disease, sexual health, oncology). It directly competes with Roche's cobas and Liat platforms across hospital, reference lab, and point-of-care settings.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Roche Molecular Systems social profiles
Digital presenceRoche Molecular Systems financial estimates
Financial estimateRevenue estimate
Valuation estimate
Roche Molecular Systems leadership team
Management profileNumber of profiles
Profiles2 records
Roche Molecular Systems funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Roche Molecular Systems M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Roche Molecular Systems
What does Roche Molecular Systems do?
Roche Molecular Systems develops, manufactures, and commercializes molecular diagnostic instruments, PCR-based assays and reagents, pre-analytical automation, and digital integration software used by clinical laboratories, hospitals, blood screening facilities, and point-of-care settings. The portfolio covers infectious disease screening and diagnosis, cervical cancer screening, sexual health, respiratory pathogen detection, transplant transmitted infection screening, and oncology testing, with thousands of cobas and LightCycler systems installed globally.
Is Roche Molecular Systems a public or private company?
Roche Molecular Systems is a private company. It is classified as corporate owned and is currently operating.
When was Roche Molecular Systems founded?
Roche Molecular Systems was founded in 1991. It employs 5,001 to 10,000 people.
Where is Roche Molecular Systems based?
Roche Molecular Systems is headquartered in Pleasanton, United States, in the North America region.
How does Roche Molecular Systems make money?
Three revenue lines are on record. Molecular Diagnostic Instruments and Systems are the primary driver. The others are molecular Assays and Reagents and service and Support Contracts.
Who are Roche Molecular Systems's main competitors?
Emerging players on record are Rheonix, DiaSorin and Seegene. Direct peers are Hologic, bioMérieux, Becton Dickinson (BD), QIAGEN, Abbott Molecular, QuidelOrtho and Cepheid (Danaher).
Does Roche Molecular Systems have an API?
No public API is recorded for Roche Molecular Systems.
What industry is Roche Molecular Systems in?
Roche Molecular Systems's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAHAAAD, Molecular Diagnostics (PCR/NAAT/NGS-based IVD), with a secondary code of HLAHAOAI, Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges). Its NAICS code is 325413 and its SIC code is 2835.